News

Investors flocked to Pfizer (NYSE: PFE) stock on Monday following some highly encouraging news about one of the company's pipeline drugs. The holy grail of pharmaceutical companies and biotechs is

Investors flocked to Pfizer (NYSE: PFE) stock on Monday following some highly encouraging news about one of the company's pipeline drugs. The holy grail of pharmaceutical companies and biotechs is

On May 16, Pfizer (NYSE: PFE) announced that it was going to take out $31 billion in fresh debt to pay for its purchase of Seagen (NASDAQ: SGEN), an oncology drug developer. In total, it'll pay $43

On May 16, Pfizer (NYSE: PFE) announced that it was going to take out $31 billion in fresh debt to pay for its purchase of Seagen (NASDAQ: SGEN), an oncology drug developer. In total, it'll pay $43

Equities experienced a bear market in 2022, and although things have improved significantly over the past few months, it's impossible to say whether we are out of the woods. However, some

Buying growth stocks on the cheap can be a great way to build wealth for investors with enough patience. This is because the strategy combines the high return potential of growth investing with the

Long-term investors recognize the benefits of a buy-and-hold strategy. The key to earning good returns is to buy good growth stocks and hold them while ignoring short-term headwinds. While 2022 was

Long-term investors recognize the benefits of a buy-and-hold strategy. The key to earning good returns is to buy good growth stocks and hold them while ignoring short-term headwinds. While 2022 was

Long-term investors recognize the benefits of a buy-and-hold strategy. The key to earning good returns is to buy good growth stocks and hold them while ignoring short-term headwinds. While 2022 was

Amid the start of the COVID-19 pandemic, big pharma companies like Pfizer (NYSE: PFE) began expedited clinical trials of COVID-19 vaccines and antiviral treatments. And a combination of incredible

Amid the start of the COVID-19 pandemic, big pharma companies like Pfizer (NYSE: PFE) began expedited clinical trials of COVID-19 vaccines and antiviral treatments. And a combination of incredible

We don't have a modern-day Paul Revere riding a horse through the streets shouting that a recession is coming. But we don't need one, as there are plenty of economists, analysts, and even the

A significant miss on quarterly earnings combined with a big change in its C-suite put a damper on CymaBay Therapeutics (NASDAQ: CBAY) stock this week. According to data compiled by S&P Global

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months

Inflation rates may finally be cooling down from last year's unnerving levels. However, prices are still rising at a pace above long-term averages, so consumers can't breathe easy just yet -- and

Inflation rates may finally be cooling down from last year's unnerving levels. However, prices are still rising at a pace above long-term averages, so consumers can't breathe easy just yet -- and

Inflation rates may finally be cooling down from last year's unnerving levels. However, prices are still rising at a pace above long-term averages, so consumers can't breathe easy just yet -- and

Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics (NASDAQ: VKTX) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares are

There's been lots of excitement surrounding Novavax (NASDAQ: NVAX). The company beat earnings expectations for the first quarter as it has been slashing expenses, and recent clinical trials --

Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If

Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If